Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study

Brett Sheppard, Jeffrey A. Norton, John L. Doppman, Paul N. Maton, Jerry D. Gardner, Robert T. Jensen

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

As part of a study to manage islet cell tumors in patients with multiple endocrine neoplasia (MEN), patients with MEN I and Zollinger-Ellison syndrome (ZES) underwent surgery if a pancreatic islet cell tumor was identified on imaging studies. Patients with MEN I and either insulinoma or vasoactive intestinal polypeptide tumor (VIPoma) underwent surgery whether or not a tumor was identified. Each patient underwent preoperative portal venous sampling (PVS). Nine patients with MEN I and one with MEN II underwent surgery; seven had ZES, one had insulinoma, one had VIPoma, and one had both insulinoma and ZES. Eight of the nine patients with MEN I had an identifiable hormone gradient on PVS. Islet cell tumors were removed from the pancreas of each patient; two patients also had duodenal wall tumors, and three patients had malignant islet cell tumors. No patient with ZES and MEN I was cured of ZES despite the fact that islet cell tumor was removed from the region of the gastrin gradient in five of six patients. The single patient with MEN II and ZES and the three additional patients with MEN I and either insulinoma or VIPoma were cured by islet cell tumor resection. The results indicate that islet cell tumors in patients with MEN I can be both extrapancreatic and malignant. In patients with MEN I and ZES, ZES cannot be cured by tumor resection, and PVS cannot be used to select patients for curative surgery. It appears that gastrinoma in patients with MEN II, as well as either insulinoma or VIPoma in patients with MEN 1, can be cured by islet cell tumor resection.

Original languageEnglish (US)
Pages (from-to)1108-1118
Number of pages11
JournalSurgery
Volume106
Issue number6
StatePublished - 1989
Externally publishedYes

Fingerprint

Multiple Endocrine Neoplasia
Islet Cell Adenoma
Prospective Studies
Zollinger-Ellison Syndrome
Insulinoma
Vipoma
Neoplasms
Islet Cell Carcinoma
Gastrinoma

ASJC Scopus subject areas

  • Surgery

Cite this

Sheppard, B., Norton, J. A., Doppman, J. L., Maton, P. N., Gardner, J. D., & Jensen, R. T. (1989). Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study. Surgery, 106(6), 1108-1118.

Management of islet cell tumors in patients with multiple endocrine neoplasia : A prospective study. / Sheppard, Brett; Norton, Jeffrey A.; Doppman, John L.; Maton, Paul N.; Gardner, Jerry D.; Jensen, Robert T.

In: Surgery, Vol. 106, No. 6, 1989, p. 1108-1118.

Research output: Contribution to journalArticle

Sheppard, B, Norton, JA, Doppman, JL, Maton, PN, Gardner, JD & Jensen, RT 1989, 'Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study', Surgery, vol. 106, no. 6, pp. 1108-1118.
Sheppard B, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT. Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study. Surgery. 1989;106(6):1108-1118.
Sheppard, Brett ; Norton, Jeffrey A. ; Doppman, John L. ; Maton, Paul N. ; Gardner, Jerry D. ; Jensen, Robert T. / Management of islet cell tumors in patients with multiple endocrine neoplasia : A prospective study. In: Surgery. 1989 ; Vol. 106, No. 6. pp. 1108-1118.
@article{2efc1d4d2cba4765b64a8dfef74b5553,
title = "Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study",
abstract = "As part of a study to manage islet cell tumors in patients with multiple endocrine neoplasia (MEN), patients with MEN I and Zollinger-Ellison syndrome (ZES) underwent surgery if a pancreatic islet cell tumor was identified on imaging studies. Patients with MEN I and either insulinoma or vasoactive intestinal polypeptide tumor (VIPoma) underwent surgery whether or not a tumor was identified. Each patient underwent preoperative portal venous sampling (PVS). Nine patients with MEN I and one with MEN II underwent surgery; seven had ZES, one had insulinoma, one had VIPoma, and one had both insulinoma and ZES. Eight of the nine patients with MEN I had an identifiable hormone gradient on PVS. Islet cell tumors were removed from the pancreas of each patient; two patients also had duodenal wall tumors, and three patients had malignant islet cell tumors. No patient with ZES and MEN I was cured of ZES despite the fact that islet cell tumor was removed from the region of the gastrin gradient in five of six patients. The single patient with MEN II and ZES and the three additional patients with MEN I and either insulinoma or VIPoma were cured by islet cell tumor resection. The results indicate that islet cell tumors in patients with MEN I can be both extrapancreatic and malignant. In patients with MEN I and ZES, ZES cannot be cured by tumor resection, and PVS cannot be used to select patients for curative surgery. It appears that gastrinoma in patients with MEN II, as well as either insulinoma or VIPoma in patients with MEN 1, can be cured by islet cell tumor resection.",
author = "Brett Sheppard and Norton, {Jeffrey A.} and Doppman, {John L.} and Maton, {Paul N.} and Gardner, {Jerry D.} and Jensen, {Robert T.}",
year = "1989",
language = "English (US)",
volume = "106",
pages = "1108--1118",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Management of islet cell tumors in patients with multiple endocrine neoplasia

T2 - A prospective study

AU - Sheppard, Brett

AU - Norton, Jeffrey A.

AU - Doppman, John L.

AU - Maton, Paul N.

AU - Gardner, Jerry D.

AU - Jensen, Robert T.

PY - 1989

Y1 - 1989

N2 - As part of a study to manage islet cell tumors in patients with multiple endocrine neoplasia (MEN), patients with MEN I and Zollinger-Ellison syndrome (ZES) underwent surgery if a pancreatic islet cell tumor was identified on imaging studies. Patients with MEN I and either insulinoma or vasoactive intestinal polypeptide tumor (VIPoma) underwent surgery whether or not a tumor was identified. Each patient underwent preoperative portal venous sampling (PVS). Nine patients with MEN I and one with MEN II underwent surgery; seven had ZES, one had insulinoma, one had VIPoma, and one had both insulinoma and ZES. Eight of the nine patients with MEN I had an identifiable hormone gradient on PVS. Islet cell tumors were removed from the pancreas of each patient; two patients also had duodenal wall tumors, and three patients had malignant islet cell tumors. No patient with ZES and MEN I was cured of ZES despite the fact that islet cell tumor was removed from the region of the gastrin gradient in five of six patients. The single patient with MEN II and ZES and the three additional patients with MEN I and either insulinoma or VIPoma were cured by islet cell tumor resection. The results indicate that islet cell tumors in patients with MEN I can be both extrapancreatic and malignant. In patients with MEN I and ZES, ZES cannot be cured by tumor resection, and PVS cannot be used to select patients for curative surgery. It appears that gastrinoma in patients with MEN II, as well as either insulinoma or VIPoma in patients with MEN 1, can be cured by islet cell tumor resection.

AB - As part of a study to manage islet cell tumors in patients with multiple endocrine neoplasia (MEN), patients with MEN I and Zollinger-Ellison syndrome (ZES) underwent surgery if a pancreatic islet cell tumor was identified on imaging studies. Patients with MEN I and either insulinoma or vasoactive intestinal polypeptide tumor (VIPoma) underwent surgery whether or not a tumor was identified. Each patient underwent preoperative portal venous sampling (PVS). Nine patients with MEN I and one with MEN II underwent surgery; seven had ZES, one had insulinoma, one had VIPoma, and one had both insulinoma and ZES. Eight of the nine patients with MEN I had an identifiable hormone gradient on PVS. Islet cell tumors were removed from the pancreas of each patient; two patients also had duodenal wall tumors, and three patients had malignant islet cell tumors. No patient with ZES and MEN I was cured of ZES despite the fact that islet cell tumor was removed from the region of the gastrin gradient in five of six patients. The single patient with MEN II and ZES and the three additional patients with MEN I and either insulinoma or VIPoma were cured by islet cell tumor resection. The results indicate that islet cell tumors in patients with MEN I can be both extrapancreatic and malignant. In patients with MEN I and ZES, ZES cannot be cured by tumor resection, and PVS cannot be used to select patients for curative surgery. It appears that gastrinoma in patients with MEN II, as well as either insulinoma or VIPoma in patients with MEN 1, can be cured by islet cell tumor resection.

UR - http://www.scopus.com/inward/record.url?scp=0024333110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024333110&partnerID=8YFLogxK

M3 - Article

C2 - 2573957

AN - SCOPUS:0024333110

VL - 106

SP - 1108

EP - 1118

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -